While between-group differences did not reach statistical significance, the observed trends toward enhanced benefits among patients with poor baseline adherence represent important mechanistic signals that may become more pronounced over longer follow-up as adherence patterns degrade, supporting the rationale for adequately powered, longer-duration trials.
← all excerpts
A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trial.
1
—
—